• MindMaze outlined a commercial-stage AI-powered neurotherapeutics platform spanning in-clinic care, outpatient rehabilitation, home treatment, monitoring, telehealth.
• Targeted large neurology markets including stroke, dementia, traumatic brain and spinal injury, Parkinson’s disease.
• Reported 35,000+ patients treated, 27 completed clinical studies, 13 ongoing studies, 12 regulatory clearances, 1 US at-home reimbursement code.
• Highlighted US$1.2 billion monthly data points feeding an AI layer to support personalization, triage, prescription, autonomous therapy development.
• Disclosed CHF 6.3 million cash as of June 30, 2026, no financial debt, 170 million shares outstanding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindMaze Therapeutics Holding SA published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.